تقرير
PARPi after PARPi in epithelial ovarian cancer.
| العنوان: | PARPi after PARPi in epithelial ovarian cancer. |
|---|---|
| المؤلفون: | Essel KG; University of Oklahoma HSC, Oklahoma City, OK, United States., Behbakht K; University of Colorado School of Medicine, Denver, CO, United States., Lai T; University of California Los Angeles, Los Angeles, CA, United States., Hand L; University of Pittsburgh, Pittsburgh, PA, United States., Evans E; University of Oklahoma HSC, Oklahoma City, OK, United States., Dvorak J; University of Oklahoma HSC, Oklahoma City, OK, United States., Ding K; University of Oklahoma HSC, Oklahoma City, OK, United States., Konecny G; University of California Los Angeles, Los Angeles, CA, United States., Moore KN; The University of Oklahoma, Stephenson Cancer Center, Oklahoma City, OK, United States. |
| المصدر: | Gynecologic oncology reports [Gynecol Oncol Rep] 2021 Jan 11; Vol. 35, pp. 100699. Date of Electronic Publication: 2021 Jan 11 (Print Publication: 2021). |
| نوع المنشور: | Case Reports |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Country of Publication: Netherlands NLM ID: 101652231 Publication Model: eCollection Cited Medium: Print ISSN: 2352-5789 (Print) Linking ISSN: 23525789 NLM ISO Abbreviation: Gynecol Oncol Rep Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Amsterdam : Elsevier, [2013]- |
| مستخلص: | The objective of this study was to describe the treatment experience of patients with recurrent epithelial ovarian cancer who are retreated with an inhibitor of poly(ADP-ribose)-polymerase (PARPi). We conducted a multi-institutional, retrospective review of ovarian cancer patients who received ≥2 lines of therapy containing a PARPi. Demographic, clinical, and pathological data were analyzed with descriptive statistics. Twenty-two patients were identified. For initial PARPi (PARPi1), 12 patients (54.5%) received veliparib, 7 (31.8%) olaparib and 3 (13.6%) rucaparib resulting in 10 patients who had no evidence of disease at the completion of therapy (NED), 3 partial responses (PR), 4 stable disease (SD), and 3 progressive disease (PD). (All 10 CRs involved veliparib given in conjunction with cytotoxic chemotherapy). PARPi1 was used as maintenance in 2 patients. PARPi1 was discontinued because planned number of cycles was reached (n = 10), progression (n = 8), toxicity (n = 2), other (n = 2). For second PARPi (PARPi2), 10 patients (45.4%) received niraparib, 6 (27.3%) olaparib, and 6 (27.3%) rucaparib resulting in 3 PR, 13 SD, and 3 PD. PARPi2 was used as maintenance in 3 patients. The 3 patients who experienced a PR to PARPi2 had a BRCA mutation and were NED following PARPi1. PARPi2 was discontinued because of progression (n = 13), toxicity (n = 6), other (n = 2). One patient currently remains on PARPi2. Toxicity after PARPi1 was not associated with toxicity from PARPi2 (p > 0.05). With 3 approved PARPi for different indications including frontline and recurrence, the opportunity to reuse PARPi has increased. Characterizing those who should be re-challenged is an important initiative moving forward. Competing Interests: The authors wish to report that there is no conflict of interest to disclose with the following exceptions: KG Essel reports that she is a former shareholder of Johnson & Johnson. GE Konecny has served on speakers bureaus for AstraZeneca and Clovis Oncology; has received research funding from Amgen and Merck; and has received honorarium from Novartis. KN Moore reports personal fees and other from Astra Zeneca, grants, personal fees and other from Genentech/Roche, grants, personal fees and other from Immunogen, grants, personal fees and other from Clovis, grants, personal fees and other from Tesaro, personal fees and other from Pfizer, personal fees from Janssen, personal fees from Aravive, personal fees from VBL Therapeutics, personal fees and other from Onco Med, personal fees from Samumed, grants and other from Lilly, personal fees from Eisai, outside the submitted work. (© 2021 The Authors.) |
| References: | N Engl J Med. 2019 Dec 19;381(25):2403-2415. (PMID: 31562800) Cancer Discov. 2019 Feb;9(2):210-219. (PMID: 30425037) Lancet Oncol. 2019 Apr;20(4):570-580. (PMID: 30880072) Nat Commun. 2018 Sep 28;9(1):3970. (PMID: 30266954) N Engl J Med. 2018 Dec 27;379(26):2495-2505. (PMID: 30345884) Nat Commun. 2018 May 10;9(1):1849. (PMID: 29748565) N Engl J Med. 2019 Dec 19;381(25):2391-2402. (PMID: 31562799) Lancet Oncol. 2014 Oct;15(11):1207-14. (PMID: 25218906) N Engl J Med. 2019 Dec 19;381(25):2416-2428. (PMID: 31851799) |
| فهرسة مساهمة: | Keywords: Ovarian cancer; PARP inhibitor |
| تواريخ الأحداث: | Date Created: 20210204 Latest Revision: 20210206 |
| رمز التحديث: | 20221213 |
| مُعرف محوري في PubMed: | PMC7840844 |
| DOI: | 10.1016/j.gore.2021.100699 |
| PMID: | 33537389 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 2352-5789 |
|---|---|
| DOI: | 10.1016/j.gore.2021.100699 |